A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Tradipitant (Primary)
  • Indications Pruritus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2017 Data from this trial will be presented at the 9th World Congress of Itch (2017), according to a Vanda Pharmaceuticals Inc. media release.
    • 13 Sep 2017 Primary endpoint has not been met. (Efficacy of tradipitant relative to placebo in reducing chronic pruritus as measured by the Visual Analogue Scale (VAS).), according to a Vanda Pharmaceuticals media release
    • 13 Sep 2017 According to a Vanda Pharmaceuticals media release, Gil Yosipovitch is investigator in this study. The detailed results of this study are expected to be presented in upcoming meetings and prepared for peer reviewed publications.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top